BDH INDUSTRIES LTD.

Established in 1990 as a privately held entity, BDH Industries (BDHIL) underwent a transition to a public limited company in 1994. Originally formed to acquire the operations of Bombay Drug House Pvt Ltd, BDHIL merged with the latter in 1994, thereafter focusing on the production of various drug formulations spanning antibiotic, anti-inflammatory, and antimicrobial segments. BDHIL's scope extends to the manufacturing of therapeutic formulations across a broad spectrum of pharmaceuticals. The company provides a comprehensive suite of Oral Solid Dosage (OSD) technologies, with its research and development center in Kandivali, Mumbai, capable of undertaking projects in new Novel Drug Delivery System (NDDS) formulations. In February 1995, BDHIL launched a public issue, raising Rs 6.10 crore to modernize production facilities and enhance long-term working capital. BDHIL also entered into a Memorandum of Understanding (MoU) with Nepothene Group Pvt Ltd, Nepal, to assist in establishing a pharmaceutical company there. Commercial production for the expansion and modernization project commenced in May 1999, with further expansion efforts undertaken during the 2000-2001 fiscal year, financed through term loans from banks, with Rs. 152.21 lacs repaid. Additionally, BDHIL installed two 0.8 MW wind turbine units in Jaisalmer Dist., Rajasthan. Recently, the company diversified into the agro-products business in 2021-22.